Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Sep;55(9):1471-1482.
doi: 10.1038/s41588-023-01485-w. Epub 2023 Aug 31.

GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture

Collaborators
Meta-Analysis

GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture

International League Against Epilepsy Consortium on Complex Epilepsies. Nat Genet. 2023 Sep.

Abstract

Epilepsy is a highly heritable disorder affecting over 50 million people worldwide, of which about one-third are resistant to current treatments. Here we report a multi-ancestry genome-wide association study including 29,944 cases, stratified into three broad categories and seven subtypes of epilepsy, and 52,538 controls. We identify 26 genome-wide significant loci, 19 of which are specific to genetic generalized epilepsy (GGE). We implicate 29 likely causal genes underlying these 26 loci. SNP-based heritability analyses show that common variants explain between 39.6% and 90% of genetic risk for GGE and its subtypes. Subtype analysis revealed markedly different genetic architectures between focal and generalized epilepsies. Gene-set analyses of GGE signals implicate synaptic processes in both excitatory and inhibitory neurons in the brain. Prioritized candidate genes overlap with monogenic epilepsy genes and with targets of current antiseizure medications. Finally, we leverage our results to identify alternate drugs with predicted efficacy if repurposed for epilepsy treatment.

PubMed Disclaimer

Conflict of interest statement

G.L.C. is in receipt of research funding from Congenica and Janssen Pharmaceuticals and has conducted consultancy for Ono Pharmaceuticals. S.F.B. received funding from UCB Pharma and Eisai and has been a consultant for Praxis Precision Medicines and Sequiris. Q.S.L. is an employee of Janssen Research & Development, LLC and a shareholder in Johnson & Johnson, which is the parent company of the Janssen companies. B.M.N. currently serves as a member of the scientific advisory board at Deep Genomics and Neumora (previously RBNC) and as a consultant for Camp4 Therapeutics. S.P. is an employee and shareholder of AstraZeneca. U.U., S.M., H. Stefansson and K.S. are employees of deCODE genetics/Amgen.

Figures

Fig. 1
Fig. 1. Manhattan plot of multi-ancestry all epilepsy (n = 29,944), focal epilepsy (n = 16,384) and genetic generalized epilepsy (n = 7,407) genome-wide meta-analyses, obtained by fixed-effects meta-analysis weighted by effective sample sizes.
The red line shows the genome-wide significance threshold (5 × 108). Chromosome and position are displayed on the x axis, and two-sided −log10 P value is on the y axis. New genome-wide significant loci are highlighted in red, and loci previously associated with epilepsy in orange. New loci were those previously unreported as GWAS significant in previous epilepsy GWASs. Annotated genes are those implicated by our gene prioritization analyses. See Supplementary Fig. 7 for QQ plots. QQ plots, quantile–quantile plot.
Fig. 2
Fig. 2. Genetic correlations of epilepsy with other phenotypes.
The genetic correlation coefficient was calculated with LDSC and is denoted by color scale from −1 (red; negatively (anti-)correlated) to +1 (blue; positively correlated). The square size relates to the absolute value of the corresponding correlation coefficient. Single asterisk indicates two-sided P < 0.05 and double asterisk indicates two-sided P < 0.0009 (Bonferroni corrected). Source data

References

    1. Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–482. doi: 10.1111/epi.12550. - DOI - PubMed
    1. Fiest KM, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88:296–303. doi: 10.1212/WNL.0000000000003509. - DOI - PMC - PubMed
    1. Scheffer IE, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512–521. doi: 10.1111/epi.13709. - DOI - PMC - PubMed
    1. International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat. Commun. 2018;9:5269. doi: 10.1038/s41467-018-07524-z. - DOI - PMC - PubMed
    1. Epi4K Consortium & Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in common epilepsies: a case–control sequencing study. Lancet Neurol. 16, 135–143 (2017). - PubMed

Publication types